HIGHLIGHTS
- who: Sjoerd P. F. T. Nota from the United Kingdom Central South University, China have published the research: Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy, in the Journal: (JOURNAL)
- what: The authors explore chimeric antigen receptor (CAR) T_cell therapy, a tumor killing mechanism that is independent of HLAI antigen expression or functionality. The authors focus on chondroitin sulfate proteoglycan 4 (CSPG4) as a potential immunotherapeutic target in chondrosarcoma based on the discovery that it is highly expressed in chemically-induced rat chondrosarcoma, and originally identified as rat chondroitin . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.